https://www.selleckchem.com/pr....oducts/dss-crosslink
Overall, 9 of 11 relapses were successfully treated with canakinumab treatment intensification or re-introduction. At last visit, 18% of patients were off treatment due to remission and 26% due to disease activity. Canakinumab had a significant corticosteroid sparing effect allowing weaning in 21 of 41 cases. Infections (20%, severe 4%) and leucopenia (6%) led to treatment cessation in one patient. High rates of sustained remission were observed in this, largest so far, real-life cohort of adult patients with refractory Still's
Like
Comment
Share
